The phototherapy equipment market is valued at USD 0.66 billion in 2026 and is forecast to reach USD 0.82 billion by 2031, advancing at a compound annual growth rate of 4.4 percent. This measured expansion reflects durable structural demand rather than cyclical acceleration, anchored primarily in rising neonatal jaundice incidence and broadening dermatological applications. Preterm birth rates and heightened clinical awareness of bilirubin management protocols drive persistent equipment adoption within hospital neonatal intensive care units, where underdeveloped liver function in vulnerable infants creates acute intervention need.
What is driving growth
Neonatal jaundice incidence remains the primary demand anchor, with newborns’ hepatic immaturity creating bilirubin accumulation risk during critical early-life windows. Rising birth rates across Asia-Pacific, North America, and select emerging regions, combined with improved diagnostic protocols in hospital settings, expand case detection and treatment initiation. Broader clinical acceptance of phototherapy for dermatological conditions including psoriasis and vitiligo, alongside product innovation in LED and excimer wavelength technologies, diversifies application scope beyond neonatal care. Government-funded healthcare infrastructure modernization programs and neonatal care expansion initiatives in developing economies establish purchasing cycles independent of commercial pressures, ensuring baseline equipment procurement aligned with public health priorities.
Restraints and challenges
Clinical alternatives including exchange transfusion, topical biologics, and targeted dermatological pharmacotherapies displace phototherapy from first-line treatment protocols in developed healthcare systems, limiting per-capita device utilization. Raw material cost volatility and logistical disruptions compress manufacturer margins, particularly for regional suppliers lacking supply chain scale. Fragmented regulatory frameworks across North America, Europe, and Asia-Pacific extend product development timelines and approval costs, while rising environmental and safety standards mandate design iteration and revalidation, imposing capital barriers that disadvantage smaller competitors.
Simultaneously, increasing prevalence of psoriasis, vitiligo, acne, and eczema expands dermatological treatment demand across hospitals, specialty clinics, and emerging homecare settings. Conventional phototherapy equipment led the market with an 80.0% share in 2026, dominating through user-friendly design and established clinical acceptance, though LED-based systems and advanced wavelength technologies are gaining traction. By end user, hospitals registered the highest utilization due to concentrated neonatal case volumes and infrastructure investment cycles.
Geographically, India is projected to achieve 8.0% CAGR, substantially exceeding global growth rates as healthcare spending expands and neonatal care infrastructure develops. Skin disease applications are expanding at an elevated rate relative to neonatal uses. Competitive dynamics involve multinational conglomerates including GE HealthCare, Natus Medical, and Phothera alongside regional specialists such as Shanghai SIGMA High-tech, Fanem, and Phoenix Medical Systems.
Companies profiled
- Co. KGaA
- GE HealthCare
- Natus Medical
- Phothera
- Shanghai SIGMA High-tech
- Fanem
- Phoenix Medical Systems
- SMEs due to their strong product portfolio
For complete market sizing, forecasts, and competitive intelligence, read the full Phototherapy Equipment Market — covering growth drivers, regional analysis, and leading company profiles through 2033.